HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Natural history of chronic hepatitis B in Euro-Mediterranean and African countries.

Abstract
Data derived from population, case-control, and cohort studies conducted in several Euro-Mediterranean and African countries disclose impressive similarities in the age and modes of hepatitis B virus (HBV) transmission and in the prevalence, duration, and outcome of the four phases of the natural history of chronic infection. Perinatal HBV infection is rare while the vast majority of chronic infections originate from horizontal HBV transmission to infants and children. HBeAg loss and seroconversion to anti-HBe occur in a few years time, usually during the second decade of life. HBeAg-negative/anti-HBe-positive chronic hepatitis B (CHB), predominates in these countries being 7-9 times more frequent than HBeAg-positive CHB. The predominance of HBeAg-negative CHB is largely linked to the molecular characteristics of HBV genotype D prevailing in European and African countries of the Mediterranean basin and of genotype E and subgenotype A1 that prevail in the other parts of Africa. The molecular characteristics of the African subgenotype A1 differ from those of European subgenotype A2 explaining the fact that patients infected subgenotype A1 demonstrate an earlier loss of HBeAg and seroconversion to anti-HBe during the natural course of HBV infection compared to those infected with subgenotype A2. It is proposed that the molecular characteristics of HBV genotypes and subgenotypes prevailing in Euro-Mediterranean and African countries acting in concert with host and environmental factors largely determine the natural history of chronic HBV infection and its significant differences from countries of HBV genotype C and B and of subgenotype Ae predominance. The knowledge of the natural history of chronic HBV infection in Euro-Mediterranean and African countries combined with wide screening programs for prompt recognition and treatment of chronic HBV infection both in its HBeAg-positive and -negative immune reactive phases can be expected to increase the efficacy of current and future therapeutic strategies.
AuthorsStephanos J Hadziyannis
JournalJournal of hepatology (J Hepatol) Vol. 55 Issue 1 Pg. 183-91 (Jul 2011) ISSN: 1600-0641 [Electronic] Netherlands
PMID21238520 (Publication Type: Historical Article, Journal Article, Review)
CopyrightCopyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Hepatitis B Antibodies
  • Hepatitis B e Antigens
Topics
  • Africa (epidemiology)
  • Europe (epidemiology)
  • Female
  • Hepatitis B Antibodies (blood)
  • Hepatitis B e Antigens (blood)
  • Hepatitis B, Chronic (epidemiology, etiology, history, virology)
  • History, 20th Century
  • History, 21st Century
  • Humans
  • Male
  • Mediterranean Region (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: